Significant Ownership of Slate Path Capital LP

Signature - Title
/s/ Thomas Hansen - By: Jades GP, LLC, General Partner, By: Thomas Hansen, Chief Financial Officer and Chief Operating Officer
Location
New York, NY
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by Slate Path Capital LP.

Notify me when Slate Path Capital LP files a new Schedule 13D/G report.

⭐ Subscribe ⭐

Significant Ownership of Slate Path Capital LP

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
TVRD Tvardi Therapeutics, Inc. Common stock, par value $0.001 per share 7.5% $19.3M 704K Slate Path Capital LP Jun 30, 2025
RKT Rocket Companies, Inc. Class A common stock, par value $0.00001 per share 2% $375M 19.4M Slate Path Capital LP Sep 30, 2025
CUE Cue Biopharma, Inc. Common stock, par value $0.001 per share 1.4% $790K 919K Slate Path Capital LP Dec 31, 2024
CYCN Cyclerion Therapeutics, Inc. Common Stock, no par value 0% $0 0 Slate Path Capital LP Nov 30, 2024

Schedules 13D/G Reported by Slate Path Capital LP:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Date Filed
* An asterisk sign (*) next to the price indicates that the price is likely invalid.